I've been relatively optimistic about St. Jude Medical's (NYSE:STJ) long-term prospects as the company navigates its current multi-year lull in growth. The company has a legitimate presence in important markets like cardiac rhythm management, atrial fibrillation, neurostimulation, and heart valve replacement, plus a pipeline that could reignite growth. With all of that said, it's still getting harder to ignore the realities of just how growth-challenged the company is in the here and now. Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock to own for a little while yet.
Please read more here:
http://www.investopedia.com/stock-analysis/041813/broad-weakness-makes-it-harder-st-jude-today-stj-bsx-mdt-ew-jnj-atrc.aspx
Investopedia: Broad Weakness Makes It Harder To Like St. Jude Today
0 comments:
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.